AVITA Therapeutics (ASX:AVH) share price climbs higher on reverse ageing project

The AVITA Therapeutics Inc (ASX:AVH) share price is pushing higher after announcing a new project which aims to reverse ageing…
The post AVITA Therapeutics (ASX:AVH) share price climbs higher on reverse ageing project appeared first on Motley Fool Australia. –

The AVITA Therapeutics Inc (ASX: AVH) share price is pushing higher on Monday following the release of an announcement.

At the time of writing, the regenerative medicine company’s shares are up over 2.5% to $6.10.

Why is the AVITA share price pushing higher?

Investors have been buying the company’s shares this morning after it announced a preclinical research collaboration with Houston Methodist Research Institute.

According to the release, the collaboration will see the pairing of AVITA’s proprietary Spray-On Skin Cells with Houston Methodist Research Institute’s expertise in reversing cellular ageing.

The project is ultimately seeking to establish proof-of-concept for the development of a novel approach to reverse ageing and rejuvenate skin. It also includes the potential for broader applicability, such as scar revision and wound healing.

In addition to this, AVITA has entered into an option agreement to negotiate an exclusive, worldwide license to this patented technology for skin applications. It also has the first right of negotiation to technologies emerging from the collaboration for potential further development and commercialisation.

Management commentary.

AVITA Therapeutics’ Chief Executive Officer, Dr. Mike Perry, commented: “The Houston Methodist Research Institute is at the forefront of developing cutting-edge approaches for reversing cellular aging, and we look forward to working together on the exploration of combining their technology with AVITA Therapeutics’ proprietary Spray-on Skin Cells to rejuvenate aging skin.”

“This collaboration expands our pipeline to include exploration of modified-cells delivery and is another milestone in our commitment to harnessing the promise of regenerative medicine and unlocking the full potential of our technology platform to improve patients’ lives through skin restoration,” he added.

This sentiment was echoed by the Houston Methodist Research Institute.

The Institute’s Chair of the Department of Cardiovascular Sciences, John Cooke, M.D., Ph.D., commented: “AVITA Therapeutics’ innovative platform has advanced care for burn patients, and we are encouraged by the progress we have seen with our technology in improving cell function through our progeria research.”

“We look forward to collaborating with AVITA to combine our respective technology platforms to explore a potential new approach to reverse aging and improve functionality of skin. Our experience in RNAbased methods to regenerate blood vessels and reverse age-related endotheliopathy is directly relevant to skin repair and rejuvenation,” he concluded.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of June 30th

More reading

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Avita Medical Limited. The Motley Fool Australia has recommended Avita Medical Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post AVITA Therapeutics (ASX:AVH) share price climbs higher on reverse ageing project appeared first on Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!